Health care stocks advanced late Friday afternoon, with the NYSE Health Care Index up 0.2% and the Health Care Select Sector SPDR Fund (XLV) adding 1.6%.
The iShares Biotechnology ETF (IBB) climbed 1.5%.
In corporate news, Pfizer (PFE) said the US Food and Drug Administration approved a combination of its Braftovi cancer drug with Eli Lilly's (LLY) Erbitux and three other chemotherapies to treat patients with metastatic colorectal cancer. Pfizer shares rose 2.2%, and Eli Lilly added 2.1%.
RxSight (RXST) shares dropped 11% after Stifel downgraded the company's stock to hold from buy and cut its price target to $40 from $65.
Novo Nordisk (NVO) shares tumbled 17% after clinical trial results of the company's investigative weight loss drug fell short of its own expectations.
Synaptogenix (SNPX) shares jumped 16% after its board formed an independent special committee to explore strategic opportunities, including drug development platforms and new technologies and services.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。